LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $100.20.

Several research firms have weighed in on LMAT. Roth Capital restated a “buy” rating and set a $108.00 price objective on shares of LeMaitre Vascular in a report on Wednesday, November 5th. Weiss Ratings lowered shares of LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday. Cantor Fitzgerald restated a “neutral” rating and issued a $95.00 target price on shares of LeMaitre Vascular in a report on Monday, November 10th. Zacks Research upgraded shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a report on Friday, November 7th. Finally, Wells Fargo & Company reduced their price objective on LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating for the company in a research note on Friday, November 7th.

LeMaitre Vascular Stock Up 4.1%

LMAT stock opened at $87.93 on Monday. The stock’s 50 day simple moving average is $88.13 and its 200 day simple moving average is $87.05. The company has a market cap of $1.99 billion, a P/E ratio of 42.68, a price-to-earnings-growth ratio of 2.29 and a beta of 0.77. The company has a debt-to-equity ratio of 0.46, a quick ratio of 11.74 and a current ratio of 13.96. LeMaitre Vascular has a fifty-two week low of $71.42 and a fifty-two week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $0.62 EPS for the quarter, beating the consensus estimate of $0.57 by $0.05. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The firm had revenue of $61.05 million during the quarter, compared to the consensus estimate of $62.18 million. During the same quarter in the previous year, the company posted $0.49 earnings per share. The company’s quarterly revenue was up 11.4% on a year-over-year basis. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS. Q4 2025 guidance at 0.640-0.690 EPS. On average, research analysts expect that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 4th. Shareholders of record on Thursday, November 20th will be given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Thursday, November 20th. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 34.48%.

Institutional Investors Weigh In On LeMaitre Vascular

Several institutional investors have recently added to or reduced their stakes in LMAT. CIBC Bancorp USA Inc. purchased a new position in shares of LeMaitre Vascular in the third quarter worth about $799,000. Advisory Services Network LLC bought a new position in LeMaitre Vascular in the 3rd quarter worth approximately $98,000. PharVision Advisers LLC purchased a new position in LeMaitre Vascular in the 3rd quarter valued at approximately $355,000. Verition Fund Management LLC raised its holdings in LeMaitre Vascular by 136.2% during the 3rd quarter. Verition Fund Management LLC now owns 16,907 shares of the medical instruments supplier’s stock valued at $1,480,000 after acquiring an additional 9,750 shares during the period. Finally, Prosperity Wealth Management Inc. purchased a new stake in shares of LeMaitre Vascular during the third quarter worth $932,000. 84.64% of the stock is owned by hedge funds and other institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.